VERA
Vera Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.92
+3.73%Oct 2, 2026, 13:24 UTC
Vera Therapeutics announced that the ORIGIN 3 final efficacy analysis of TRUTAKNA (atacicept-vymj) in IgA nephropathy will be featured as a late-breaking oral presentation at the opening plenary session of ASN Kidney Week 2026.
Source:Sep 15, 2026, 16:28 UTC
Vera Therapeutics announced data from the ORIGIN 3 trial, sending its shares lower after an initial spike.
Source:Sep 15, 2026, 16:08 UTC
Vera Therapeutics announced positive final efficacy results from the Phase 3 ORIGIN 3 trial of its kidney disease drug tortacna in adults with primary IgA nephropathy, meeting all pre-specified endpoints.
Source:Sep 15, 2026, 10:30 UTC
Vera Therapeutics reported final two-year Phase 3 results showing its drug Trutakna stabilized kidney function and reduced kidney-related death and complications in patients with chronic autoimmune kidney disease, and said it will seek full FDA approval in the fourth quarter.
Jul 11, 2026, 18:02 UTC
Vera Therapeutics received FDA accelerated approval for TRUTAKNA (atacicept-vymj) for adults with primary IgA nephropathy at risk for disease progression.
Source:Jul 9, 2026, 12:00 UTC
Vera Therapeutics announced the appointment of Nancy Boman as Chief Regulatory Officer and the planned retirement of William Turner.
Source:Jul 7, 2026, 16:37 UTC
Vera Therapeutics received FDA accelerated approval for TRUTAKNA for adult patients with primary IgA nephropathy.